Best Peptides for Sleep (2026): What the Research Actually Shows

The peptides most studied for sleep are DSIP (delta sleep-inducing peptide), the pineal peptide epitalon, and growth-hormone-axis peptides like CJC-1295 and sermorelin. Human evidence is limited and mostly old or small; none are FDA-approved for insomnia. This guide covers mechanisms, research-cited dosing, safety, and 2026 legal status.

Sleep peptides at a glance

• Best-studied for sleep architecture: DSIP (delta sleep-inducing peptide), a nonapeptide first described in the 1970s
• Best-studied for melatonin rhythm: epitalon / epithalamin (pineal peptides)
• Most relevant to deep (slow-wave) sleep biology: GHRH-class peptides (CJC-1295, sermorelin) via the growth-hormone axis
• Human evidence level: limited — small trials, case reports, and single-group studies; large modern RCTs are absent
• Commonly cited research doses: DSIP ~25 mcg/kg IV in older studies; epitalon courses of 5–10 mg; framed as research protocols, not prescriptions
• FDA status (June 2026): none approved for sleep; DSIP (as emideltide) and epitalon are under PCAC review for the 503A compounding list on July 23–24, 2026

Which peptides are most studied for sleep?

Three groups of peptides dominate the sleep conversation, and they work through different biology.

The first is DSIP (delta sleep-inducing peptide), a nine-amino-acid peptide isolated from rabbit brain in the 1970s and named for its association with delta-wave (deep) sleep. It is the only peptide with human sleep-lab data going back decades, though those datasets are small.

The second is the pineal peptide group — epitalon (a synthetic tetrapeptide) and epithalamin (a peptide extract). These are studied less for sleep onset directly and more for their proposed effect on the pineal gland's melatonin rhythm, which underlies the timing of sleep.

The third is the growth-hormone-releasing class — GHRH analogs such as CJC-1295 and sermorelin, and growth-hormone secretagogues like ipamorelin. These are not "sleep peptides" by design; they are studied for body composition and recovery. Their relevance is indirect: growth hormone and deep sleep are biologically linked, so anything that touches the GH axis intersects with slow-wave sleep.

A practical note before going further: "best" here means best-studied and most biologically plausible — not proven, safe, or recommended. For most of these compounds, the strongest human evidence is 30–45 years old and never replicated at modern scale. See our DSIP protocol guide and epitalon protocol guide for compound-level detail.

How does DSIP affect sleep?

DSIP is a nonapeptide (molecular weight ~849) first characterized as a sleep-associated factor in rabbit brain. In a foundational review, Graf and Kastin catalogued its association with sleep, neuroendocrine, and circadian effects across multiple species, while emphasizing that its mechanism was — and remains — incompletely defined (Graf & Kastin, 1984, Neurosci Biobehav Rev) [VERIFY: exact author order; PMID 6145137 could not be fetched directly].

The most-cited human data come from a small study by Schneider-Helmert and Schoenenberger, in which six middle-aged chronic insomniacs received intravenous synthetic DSIP. The authors reported longer total sleep, higher sleep quality with fewer awakenings, and slightly more REM sleep, without daytime sedation or noted side effects (Schneider-Helmert & Schoenenberger, 1981, Experientia). This is a six-person study, not a controlled trial, and should be read as exploratory.

A separate case report from the same investigator described a 47-year-old woman with chronic delayed sleep-phase insomnia and benzodiazepine dependence whose main sleep phase advanced by roughly five hours during a week of DSIP treatment, alongside withdrawal of benzodiazepines (Schneider-Helmert, 1987, Dtsch Med Wochenschr). A single case cannot establish efficacy.

More recent work is preclinical. A 2024 study engineered a blood-brain-barrier-crossing DSIP fusion peptide and tested it in a PCPA-induced insomnia mouse model, reporting reduced wakefulness and partial restoration of neurotransmitter balance versus DSIP alone (Mu et al., 2024, Front Pharmacol). Mouse findings do not transfer directly to humans.

How do epitalon and pineal peptides affect sleep?

Epitalon (Ala-Glu-Asp-Gly) and the related extract epithalamin are studied primarily for the pineal gland and the melatonin rhythm that governs sleep timing rather than for sleep onset per se.

In elderly subjects, Korkushko and colleagues reported that epithalamin modulated the pineal gland's melatonin-producing function — increasing night-time melatonin in people whose baseline pineal activity was low, while the rhythm normalized rather than simply rose (Korkushko et al., 2004, Bull Exp Biol Med). The relevance to sleep is indirect but mechanistically coherent: melatonin timing is a core input to the sleep-wake cycle, and night melatonin tends to decline with age.

Longer-term follow-up from the same research program reported that repeated epithalamin courses in elderly cardiovascular patients were associated with normalized melatonin circadian rhythm and reduced mortality over 15 years (Korkushko et al., 2011, Bull Exp Biol Med). These results come overwhelmingly from a single research group in St. Petersburg and have not been independently replicated at scale, which is the central caveat for the entire epitalon literature. Treat the melatonin-normalization claim as plausible-but-unconfirmed, and the longevity claims as well outside the scope of sleep.

For mechanism and dosing detail, see the epitalon protocol guide.

Do growth-hormone peptides like CJC-1295 improve deep sleep?

This is where biology and marketing diverge, so the framing matters.

The real, well-established finding is that growth hormone and slow-wave (deep) sleep are linked. The most reproducible GH pulse of the day occurs shortly after sleep onset, in association with the first episode of slow-wave sleep, and the amount of GH released correlates with the amount of slow-wave sleep present (Van Cauter & Plat, 1996, J Pediatr). About 70% of GH pulses in men coincide with slow-wave sleep.

The direction researchers tested was GH-releasing hormone into sleep. In healthy young men, GHRH given during sleep produced a marked decrease in wakefulness and an almost 10-fold increase in slow-wave sleep when administered during the third REM period (Kerkhofs et al., 1993, Am J Physiol). That is a striking experimental result for GHRH itself, under controlled IV dosing.

Two cautions keep this honest. First, that effect was demonstrated for native GHRH in a lab, not for the long-acting research analog CJC-1295 or for ipamorelin; the popular claim that "CJC-1295/ipamorelin deepens sleep" is an extrapolation, not a direct trial finding. Second, the sleep-promoting effect of GHRH appears to be sex-dependent — studies have found it does not reproduce, and may even impair sleep, in women (Antonijevic et al., 2000, Psychoneuroendocrinology) [VERIFY: first author and year for the GHRH-in-women impairment finding]. So the accurate statement is: GH-axis peptides plausibly touch slow-wave-sleep biology, the human evidence is for GHRH specifically and mostly in men, and claims for the consumer-popular analogs remain unproven. See the CJC-1295 guide for the GH-axis detail.

What doses do sleep peptide studies use?

Dosing below describes what research protocols and older studies have used — it is reported context, not a recommendation. There is no FDA-approved peptide for sleep, and no validated consumer dosing for any compound on this page.

Two genuine numbers anchor the table: the GHRH-into-sleep experiment used roughly 0.3 mcg/kg timed to the third REM period (Kerkhofs et al., 1993, Am J Physiol), and the human DSIP sleep work used intravenous dosing in a six-person sample (Schneider-Helmert & Schoenenberger, 1981, Experientia). Everything else circulating online — fixed milligram "sleep stacks," nightly subcutaneous schedules — is community practice, not trial-derived.

Consult your healthcare provider before starting any peptide protocol. Self-dosing an unapproved injectable based on a 40-year-old six-person study is not a substitute for evaluating and treating insomnia properly.

Are sleep peptides safe?

Honest answer: the safety profile of these peptides for sleep in humans is not well characterized, because the human studies are small, short, and decades old.

For DSIP, the most-cited human report noted no daytime sedation or side effects in its small sample (Schneider-Helmert & Schoenenberger, 1981, Experientia), but a six-person study cannot detect uncommon harms, and there is no modern long-term human safety dataset. The peptide's broad neuroendocrine activity — effects described on hormones, neurotransmitters, and circadian patterns in the early reviews — is exactly why "it touches many systems" should read as a reason for caution, not reassurance (Graf & Kastin, 1984, Neurosci Biobehav Rev) [VERIFY: PMID 6145137 attribution].

For GH-axis peptides, the relevant safety consideration is that stimulating growth hormone is not consequence-free: GH excess is associated with insulin resistance, fluid retention, and joint symptoms, which is why GH-axis manipulation belongs under medical supervision rather than self-experimentation.

For epitalon, the human safety record comes almost entirely from one research group, so apparent tolerability has not been independently confirmed at scale (Korkushko et al., 2011, Bull Exp Biol Med).

Across all of these, a separate and underappreciated risk is product quality: because none are FDA-approved finished drugs for sleep, what a consumer actually receives may be a research-grade powder of uncertain purity, sterility, or identity. Consult your healthcare provider before starting any peptide protocol, and treat sourcing as a safety issue in its own right.

Are peptides for sleep legal in 2026?

Legal status is the fastest-moving part of this topic, and 2026 has been a pivotal year.

No peptide on this page is FDA-approved as a drug for insomnia or any sleep disorder. The compounds exist in the research/compounding space, and that space shifted in April 2026. The FDA announced it would remove 12 peptides — including DSIP (listed as emideltide) and epitalon — from Category 2 of the 503A bulk drug substances list, the bucket reserved for substances with significant safety concerns; the removal took effect on April 22, 2026 (FDA, 2026; reported by Orrick and Foley & Lardner, May 2026). Removal from Category 2 does not automatically make a substance legal to compound — it moves these peptides into a regulatory gray zone pending further action.

That further action is scheduled. The Pharmacy Compounding Advisory Committee (PCAC) will meet on July 23–24, 2026 to consider whether to recommend adding seven peptides — BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax, and epitalon — to the 503A Category 1 bulks list (FDA / PCAC, 2026, reported by Foley & Lardner). Critically, a PCAC recommendation is non-binding: even a favorable vote would require subsequent FDA notice-and-comment rulemaking, a process that typically takes more than a year. So as of June 5, 2026, both DSIP and epitalon remain in compounding limbo, and GH-axis analogs like CJC-1295 sit outside the approved-bulks pathway as well.

Legal status varies by jurisdiction; consult a lawyer for binding advice. For the full regulatory picture, see our 2026 peptide legal status tracker.

Frequently asked questions

Q: What is the best peptide for sleep? A: There is no single "best" peptide for sleep with strong human proof. DSIP (delta sleep-inducing peptide) has the most direct human sleep-lab data, but those studies are small and decades old. Epitalon is studied for the melatonin rhythm rather than sleep onset, and GH-axis peptides like CJC-1295 connect to deep (slow-wave) sleep only indirectly. None are FDA-approved for insomnia. "Best-studied" is not the same as proven, safe, or recommended — discuss any sleep concern with a healthcare provider before considering peptides.

Q: Does DSIP actually work for insomnia? A: The human evidence is limited and old. A six-person study reported longer, higher-quality sleep after intravenous DSIP (Schneider-Helmert & Schoenenberger, 1981), and a single case report described a five-hour advance in sleep phase. Recent positive results are in mice, not humans. These findings are exploratory; they have not been confirmed in large modern controlled trials. DSIP is not approved for insomnia, and individual response is unknown. Consult a healthcare provider.

Q: Can epitalon improve sleep? A: Epitalon's proposed sleep relevance is indirect, through the pineal gland and melatonin timing. Research in elderly subjects reported that the related peptide epithalamin normalized night-time melatonin in people with low baseline pineal activity (Korkushko et al., 2004). However, most of this evidence comes from one research group and has not been independently replicated at scale, and it does not directly measure insomnia outcomes. Treat the melatonin claim as plausible but unconfirmed.

Q: Do CJC-1295 and ipamorelin help you sleep? A: The biology is real but the claim is overstated. Growth hormone is released during deep slow-wave sleep, and native GHRH increased slow-wave sleep in a controlled study of healthy men (Kerkhofs et al., 1993). That study used GHRH itself, not the long-acting analog CJC-1295 or ipamorelin, and the effect did not reliably reproduce in women. So a deep-sleep benefit from these specific peptides is inferred, not demonstrated. Consult a provider before using GH-axis peptides.

Q: Is DSIP the same as melatonin? A: No. Melatonin is a hormone produced by the pineal gland that signals night-time and helps set sleep timing. DSIP is a nine-amino-acid peptide associated with delta-wave (deep) sleep that acts through different, still-incompletely-defined neuroendocrine pathways. Epitalon sits between the two conceptually — it is a peptide proposed to influence the pineal gland's melatonin output. They are not interchangeable, and they are studied for different aspects of sleep.

Q: Are sleep peptides legal in the US in 2026? A: None are FDA-approved for sleep. In April 2026 the FDA removed DSIP (emideltide) and epitalon from the 503A Category 2 list, effective April 22, 2026, but that did not make them approved — it moved them into a gray zone pending review. The PCAC will consider both for the 503A bulks list on July 23–24, 2026, though any recommendation is non-binding and would still require lengthy FDA rulemaking. Legal status varies by jurisdiction; consult a lawyer.

Q: What are the risks of using peptides for sleep? A: The main risks are unknown long-term safety (human studies are small and old), broad neuroendocrine activity that can affect hormones beyond sleep, GH-axis side effects like insulin resistance or fluid retention for growth-hormone peptides, and product-quality problems — uncertain purity, sterility, or identity in non-approved research-grade material. Because these are injectables outside approved pathways, sourcing itself is a safety concern. Consult your healthcare provider before starting any peptide protocol.

References

1. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981. PMID: 7028502. https://pubmed.ncbi.nlm.nih.gov/7028502/
2. Schneider-Helmert D. [The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia]. Dtsch Med Wochenschr. 1987. PMID: 3582201. https://pubmed.ncbi.nlm.nih.gov/3582201/
3. Kerkhofs M, Van Cauter E, Van Onderbergen A, Caufriez A, Thorner MO, Copinschi G. Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am J Physiol. 1993. PMID: 8476038. https://pubmed.ncbi.nlm.nih.gov/8476038/
4. Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr. 1996. PMID: 8627466. https://pubmed.ncbi.nlm.nih.gov/8627466/
5. Korkushko OV, et al. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bull Exp Biol Med. 2004. PMID: 15452611. https://pubmed.ncbi.nlm.nih.gov/15452611/
6. Korkushko OV, et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011. PMID: 22451889. https://pubmed.ncbi.nlm.nih.gov/22451889/
7. Mu Y, et al. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Front Pharmacol. 2024. PMC11498945. https://pmc.ncbi.nlm.nih.gov/articles/PMC11498945/
8. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. PMID: 6145137. https://pubmed.ncbi.nlm.nih.gov/6145137/ [VERIFY: author/journal not fetched directly — PubMed page returned a CAPTCHA during drafting]
9. US Food & Drug Administration. Pharmacy Compounding Advisory Committee — 503A bulk drug substances; removal of 12 peptides from Category 2 (effective April 22, 2026) and July 23–24, 2026 meeting agenda. As reported by Foley & Lardner LLP (May 2026) and Orrick, Herrington & Sutcliffe LLP (April 2026). https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/